Cell line a | Â | Drug | EF's |
---|
4197 | p53 wt b | D, M, CP | 1.3 | 3.0 | 2.6 |
4451 | p53 mut b | D, M, CP | 2.3 |
8.6
|
52
|
Be11 | p53 wtb | D, M, CP | 1.4 | 2.3 | 1.2 |
MeWo | p53 mut b | D, M, CP | 2.8 |
85
|
74
|
DU 145 | p53 mut c | V, E, CP |
4.8
| 1.5 |
4.1
|
BM1604 | p53 mut c | V, E, CP | 2.6 | 1.0 |
4.5
|
LNCaP | p53 wt c | V, E, CP | 1.4 | 1.5 | 1.6 |
- a) 4197 and 4451 are human squamous carcinoma cell lines. Be-11 and MeWo are human melanoma cell lines. The DU-145 prostatic tumour cell line was established from a metastatic central nervous system lesion. The BM 1604 cell was established from a radical prostatectomy biopsy. The LnCaP cell line was established from a supraclavicular lymph node metatstasis of a human prostate adenocarcinoma.
- D: Daunorubicin; E: Etoposide; M: Melphalan; V: Vinblastine; CP: cisplatin based on clonogenic SF 7 (survival fraction at 7 Gy) and dye staining data b) Binder et al. [4] ; c) Serafin et al. [40]